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Background: Malnutrition is associated with increased risk of premature death in humans with
inflammatory bowel disease.
Hypothesis/Objective: To determine if historical, clinical, and laboratory markers of malnutrition
in dogs at the time of histologic diagnosis of protein-losing enteropathy (PLE) caused by chronic
enteropathy (CE) or lymphangiectasia are associated with increased risk of death.
Animals: Seventy-one client-owned dogs diagnosed with PLE.
Methods: The medical records were retrospectively searched for cases of PLE, diagnosed with
CE or lymphangiectasia on the basis of histopathology of intestinal biopsies at a referral hospital.
For each case, various variables at the time of diagnostic investigation were recorded and
follow-up obtained by telephone contact with the referring veterinarian.
Results: A multivariable cox model indicated that canine chronic enteropathy activity index
(CCEAI) and blood urea concentration were significantly associated with death (P values <.01).
For each unit increase in CCEAI, the hazard of death increased by 22.9% (confidence interval
[CI]: 6.9%-41.2%). Dogs with a CCEAI of ≤8 and dogs with urea ≤7 mmol/L survived 256 days
longer (P = .001, CI: 106.7-405.4 days) and 279 days longer (P = .009, CI: 70.0-488.7 days) than
those with a CCEAI of >8 and urea >7 mmol/L on average, respectively, when followed up for
647 days.
Conclusions and Clinical Importance: Increased CCEAI and blood urea concentration at the time
of diagnosis might be predictive of death in dogs with PLE caused by CE or lymphangiectasia.
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1 | INTRODUCTION
Dogs with protein-losing enteropathy (PLE) caused by chronic enter-
opathy (CE) or lymphangiectasia have poor prognosis after failure with
immunomodulatory treatment.1 Although, various studies have aimed
to identify prognostic markers in dogs with PLE caused by CE or lym-
phangiectasia, these have led to variable and inconsistent results.1–5
To the authors' knowledge, body condition score (BCS) has been
assessed in only 1 study in dogs with PLE caused by CE, which docu-
mented that the median BCS at the time of diagnosis was not differ-
ent between dogs with PLE that had a good or bad outcome.4
However, this study used a relatively short follow-up period (ie,
4 months) to define outcome and, although not its main intention, it
did not assess the effect of BCS adjusting for other variables in a mul-
tivariable model.
Abbreviations: AIC, Akaike information criterion; BCS, body condition score;
BMI, body mass index; CCEAI, canine chronic enteropathy activity index; CE,
chronic enteropathy; CI, confidence interval; GI, gastrointestinal; IBD, inflamma-
tory bowel disease; LRT, likelihood ratio test; PH, proportional hazard; PLE, pro-
tein-losing enteropathy; RMST, restricted mean survival time.
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Body condition score in dogs is one of the measures used to
assess nutritional status.6,7 Nutritional status in dogs with PLE caused
by CE or lymphangiectasia might be important prognostically, as mal-
nutrition is associated with increased in-hospital death and duration
of stay in humans with inflammatory bowel disease (IBD).8 This study
hypothesized that, as malnutrition is associated with a weakened
immune system,9,10 the use of concurrent immunomodulatory treat-
ment in humans with IBD could lead to increased death. As immuno-
modulatory treatment is commonly used in dogs with PLE caused by
CE or lymphangiectasia, the investigation of malnutrition as a predic-
tor for death might not only help prognostication, but might help to
determine whether assisted dietary intervention at an earlier stage
optimizes response to immunomodulatory treatment and therefore
prognosis. Also, if markers of malnutrition are associated with death,
then incorporation into index measures of clinical disease activity
should be considered.
Although there is no complete agreement on the elements that
define malnutrition in human or veterinary medicine, The European
Society for Clinical Nutrition and Metabolism states that the diagnosis
of malnutrition in humans should be based on either a body mass
index (BMI) of <18.5 or a combined finding of unintentional weight
loss with either reduced BMI or a low fat free mass.11 Single micronu-
trient deficiencies such as cobalamin and folate can also help to define
malnutrition.12 Serum albumin and BMI are the most predictive of all
variables of malnutrition in human IBD patients with active disease.13
However, BMI and unintentional weight loss together with recent
nutrient intake and severity of disease might be more appropriate for
the assessment of malnutrition in human IBD patients.14
Therefore, the aim of our study was to assess whether BCS and
other indicators of malnutrition used in human IBD patients, such as
body weight, percentage weight loss, appetite, serum albumin, choles-
terol, urea, creatinine, cobalamin and folate concentrations, as well as
severity of disease and duration of clinical signs at the time of histo-
logic diagnosis can be used as predictors for death after treatment
failure in dogs with PLE caused by CE or lymphangiectasia. In our
study, severity of disease was estimated using the canine chronic
enteropathy activity index (CCEAI), which is based on the presence
and severity of 9 factors including attitude/activity, appetite, vomiting,
consistency of feces, frequency of defecation, weight loss, serum
albumin concentrations, ascites and peripheral edema, and pruritus.15
2 | MATERIALS AND METHODS
2.1 | Data collection
The medical records at the University of Bristol Small Animal Referral
Hospital were retrospectively searched for dogs presented between
January 2010 and October 2017 with a diagnosis of PLE from either a
CE or lymphangiectasia diagnosed on histopathology of endoscopi-
cally collected intestinal biopsies performed at our hospital. Inclusion
criteria included those dogs diagnosed with PLE based on biochemical
profile and consistent signs of gastrointestinal (GI) disease that had, to
rule out other causes, appropriate diagnostic investigations, including
at least an upper GI endoscopy with collection of intestinal biopsies,
and which documented CE or lymphangiectasia. A minimum follow-up
period of 4 months since discharge from the hospital was required for
inclusion into the study if the dog was still alive at the end of the
study. This minimum time period has been used in previous studies
assessing outcome in dogs with PLE.3,4 Those dogs that had died or
were euthanized after histopathology of intestinal biopsies but before
hospital discharge were also included. Exclusion criteria consisted of
those cases that did not have collection of intestinal biopsies per-
formed or were diagnosed with alimentary lymphoma. In addition,
dogs diagnosed with CE or intestinal lymphangiectasia and still alive
that were followed up <4 months since discharge from the hospital
or had incomplete medical records including an absent BCS were
also excluded. Seventy-one dogs meeting the inclusion criteria were
included in the study.
The diagnostic evaluation for each of the 71 dogs included a com-
plete blood count, serum biochemistry, serum cobalamin and folate
concentrations, transabdominal ultrasound examination and upper GI
endoscopy and collection of biopsy specimens. Of these dogs, a num-
ber had additional diagnostic procedures performed as indicated by
the history, physical examination, and ultrasound examination find-
ings: collection of intestinal biopsy specimens by lower GI endoscopy
in 29 dogs (41%), pancreatic function testing (canine pancreatic lipase
immunoreactivity in 26 dogs [37%] and trypsin-like immunoreactivity
in 37 [52%]), basal cortisol concentration or ACTH stimulation test in
47 dogs (66%), preprandial or pre- and postprandial bile acid concen-
trations in 52 dogs (73%), fecal parasitology using zinc sulfate flotation
with centrifugation in 53 dogs (75%), fecal culture (for Salmonella,
Campylobacter, and Clostridium difficile) in 45 dogs (63%), empirical
deworming in 64 dogs (90%), and urine protein:creatinine ratio in
59 dogs (83%). All medical records were reviewed by 1 of the authors
(Aarti Kathrani) and included the following information for each dog:
signalment (including breed, sex, neutering status, and age); clinical
history including duration of clinical signs, appetite, lethargy, body
weight, percentage weight loss, presence of ascites and peripheral
edema, vomiting, and diarrhea; BCS (numerical score assessed on a
9-point6 or 5-point scale16); results of diagnostic tests including labo-
ratory findings, transabdominal ultrasound examination findings,
endoscopic findings, and histopathology report; and treatment pre-
scribed. For each dog, neutering status, age, BCS, and other historical,
clinical, and laboratory markers of malnutrition used for analysis were
recorded at the time of histologic diagnosis of PLE caused by CE or
lymphangiectasia. Outcomes for each dog were obtained from medical
records as well as follow-up phone contact with the referring veteri-
nary practice.
2.2 | Data management
Many breeds were present in the dataset, most represented by only a
few individuals, limiting further breed analysis. Thus, for the purposes
of this study, only the animal's breed, classified as purebred or cross-
bred, was further assessed. The percentage weight loss was calculated
as the difference between the last recorded stable body weight based
on body weight histories obtained from the medical record from the
referring veterinarian and the body weight at admission to our hospi-
tal. The CCEAI was retrospectively calculated for each dog based on
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the history collected at admission and the referring veterinarian's
medical records.15 Appetite at diagnosis was categorized as anorexic
(appetite 1), hyporexic (appetite 2), unchanged (appetite 3), or increased
(appetite 4). Eleven out of 71 dogs (15%) had BCS assessed on a
5-point scale with the remainder of the dogs having their BCS assessed
on a 9-point scale. Therefore, the 11 dogs that had their BCS assessed
on a 5-point scale were converted to a 9-point scale by dividing their
score by 5 and multiplying by 9 and rounding to the closest half-
integer.
2.3 | Statistical analysis
Survival analysis was conducted on all dogs diagnosed with PLE
caused by CE or lymphangiectasia. The study endpoint was deter-
mined to be death because of or euthanasia because of PLE. The sur-
vival time interval from the date of PLE histologic diagnosis caused by
CE or lymphangiectasia to death was recorded. For those cases in
which survival time and cause of death were not recorded in the med-
ical records, follow-up information was obtained by telephone inter-
view with the referring veterinary practice. Dogs that were still alive
when they were lost to follow-up or still alive at the end of the study,
as well as dogs dying from causes other than PLE caused by CE or
lymphangiectasia were all right censored.
A multivariable Cox proportional hazards (PH) regression analysis
was conducted to assess the association between several markers of
malnutrition and death after treatment failure. Tied survival times
were handled using the Efron method. Initial univariable screening
was undertaken for 4 explanatory categorical variables: breed, sex,
neutering status, and appetite; and 9 quantitative variables: age, dura-
tion of clinical signs, body weight, percentage weight loss, CCEAI, urea
(mmol/L), creatinine (umol/L), BCS, and serum albumin concentrations
(g/L). These univariable analyses were carried out using the same
dataset, which contained information for each variable. Explanatory
variables were retained for multivariable analysis if a likelihood ratio
test (LRT) indicated P ≤ .20 against a null model on univariable analy-
sis. Polynomial terms were included for quantitative exploratory vari-
ables if an LRT indicated significantly improved fit. Multivariable
models underwent step-wise backward elimination to minimize Akaike
Information Criterion (AIC). The assumption of PH was tested by
post-examining the relationship between scaled Schoenfeld residuals
and time. If the PH assumption is not satisfied for a covariate of the
model, the pattern of Schoenfeld residuals was used to help identify
an appropriate time-dependent function, and then a covariate with a
time-varying effect using the “time transfer” function “tt” in the R
package “survival” was created.17 Explanatory variables included in
the final multivariable model were further evaluated individually by
using the Kaplan-Meier survival analysis. Quantitative variables were
categorized as dichotomous variables for the analysis only when a
clinically relevant cut point was possible. A log-rank test was used to
test whether the overall survival functions across groups were equal.
The difference in restricted mean survival time (RMST) between
groups was tested for 647 days of follow-up (ie, the minimum follow-
up time during which all deaths after treatment failure occurred).
Detailed information about the continuous variables cholesterol
concentrations (mmol/L), cobalamin concentrations (pmol/L), and
folate concentrations (nmol/L) was only available for 72% of the dogs
in the multivariable analysis. Therefore, to avoid reducing the number
of dogs included in the multivariable model, the association between
these variables and death was only evaluated by univariable Cox PH
regression models.
All analyses were carried out using R language version 3.4.1.17
Cox PH regression analysis and Kaplan-Meier survival analysis were
conducted using the R package “survival”17 and RMST analysis was
carried out using the “rmst2” function from the R package “survRM2.”18
Statistical significance was defined as P < .05.
3 | RESULTS
3.1 | Study population
Seventy-one dogs with PLE were included in the study: 12 intact
males, 33 neutered males, 1 intact female, and 25 neutered females.
The age of the dogs ranged from 1.2 to 13.5 years, with a median age
of 7.7 years. Breeds included Staffordshire Bull Terrier (7), Border
Collie (6), cross breed (5), German Shepherd (4), Labrador Retriever
(4), Cocker spaniel (4), Cavalier King Charles Spaniel (4), Jack Russell
Terrier (3), English Bulldog (3), Rottweiler (3), Yorkshire Terrier (2), Border
Terrier (2), Lurcher (2), Shetland Sheepdog (2), Hungarian Vizsla (2),
Greyhound (2), Weimaraner (2), Springer Spaniel (2), Cockerpoo (2),
and 1 each of the following breeds: Japanese Akita, Great Dane,
Newfoundland, Sloughi, Miniature Schnauzer, Bichon Frise, Fox Terrier,
Toy Poodle, Chihuahua, and Dachshund.
3.2 | Descriptive statistics
3.2.1 | Duration of clinical signs, appetite, BCS, body
weight, percentage weight loss, and CCEAI
Duration of clinical signs for all dogs ranged between 1 day and
1095 days (median, 60 days). Eight dogs (11%) were anorexic, 26 dogs
(37%) were hyporexic, 25 dogs (35%) had an unchanged appetite,
8 dogs (11%) were reported to be polyphagic, and appetite was unre-
ported in 4 dogs (6%) at the time of presentation. Forty-seven
dogs (66%) were under-conditioned (median, 3; range, 1 to 4), 18 dogs
(25%) were ideal-conditioned (median, 4; range, 4 to 5), and 6 dogs
(8%) were over-conditioned (median: 6 to 6-7; range: 5-6 to 8). Body
weight ranged from 2.6 to 54.9 kg with a median of 17 kg. Sixty-one
dogs (88%) had documented weight loss at the time of diagnosis;
30 (43%) had severe (≥10%; median, 17.2%; range, 10%-32%), 22
(32%) had moderate (5%-9.9%; median, 7.5%; range, 5%-9.6%), and
9 (13%) had mild (0.1%-4.9%; median 3.1%; range, 2.1%-4.7%) loss;
the remaining 10 dogs had documented 0% body weight loss and for
2 dogs, weight loss could not be objectively quantified based on the
medical records provided by the referring veterinarian. The CCEAI
ranged from 3 to 16 with a median of 8.
3.2.2 | Histologic diagnosis
All dogs had histopathology of intestinal biopsies that were collected
via upper GI endoscopy. Sixty-eight dogs (96%) were diagnosed
with a chronic inflammatory enteropathy; a total of 21 (31%) had
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lymphoplasmacytic and eosinophilic enteritis; 15 (22%) had lympho-
plasmacytic enteritis; 12 (18%) had eosinophilic enteritis; 7 (10%) had
lymphoplasmacytic, eosinophilic, and neutrophilic enteritis; 7 (10%)
had lymphoplasmacytic and neutrophilic enteritis; 3 (4%) had plasma-
cytic and eosinophilic enteritis; and 1 had each of plasmacytic enteri-
tis, lymphoplasmacytic and granulocytic enteritis, and plasmacytic and
neutrophilic enteritis. Thirteen of the 68 dogs (19%) with chronic
inflammatory enteropathy had concurrent lacteal dilatation on histo-
pathology and 9 (13%) had crypt abscesses. Three dogs were diag-
nosed with primary lymphangiectasia.
Colon biopsies were collected in 29 dogs (41%), 25 of which also
had ileal biopsies performed; 10 (15%) had lymphoplasmacytic colitis,
8 (12%) were within normal limits, 3 (4%) had lymphoplasmacytic,
neutrophilic and eosinophilic colitis, 2 (3%) had lymphoplasmacytic
and eosinophilic colitis, 2 (3%) had lymphoplasmacytic and neutro-
philic colitis, 2 (3%) had eosinophilic colitis, and 1 had each of the fol-
lowing (3%): plasmacytic and eosinophilic colitis and plasmacytic and
neutrophilic colitis.
3.2.3 | Serum albumin, cholesterol, cobalamin, folate, urea,
and creatinine concentrations
All dogs had hypoalbuminemia (median, 17.1 g/L; range, 12-29.3 g/L;
reference range, 32-38 g/L). Forty dogs (56%) had hypocholesterole-
mia, 17 dogs (24%) had cholesterol within the reference range, and
cholesterol was not measured in 14 dogs (20%) (median, 2.6 mmol/L;
range, 1.1-7.1 mmol/L; reference range, 3.5-7.0 mmol/L). Thirty-eight
dogs (54%) had cobalamin concentrations below the reference range,
23 dogs (32%) had concentrations within or above the reference
range, and 10 dogs (14%) had received supplementation before mea-
surement and therefore were not included (median, 165 pmol/L;
range, 107-748 g/L; reference range, 200-408 g/L). Thirty-three dogs
(46%) had folate concentrations below the reference range, 19 dogs
(27%) had concentrations within the reference range, 9 (13%) were
above the reference range, and 10 dogs (14%) had concentrations
that were not available for review (median, 11.4 nmol/L; range,
2.8-49.4 g/L; reference range, 12.0-30.0 nmol/L). Ten dogs (14%) had
urea concentrations above the reference range and 1 dog (1%) had
concentrations below the reference range (median, 5.0 mmol/L; range,
1.8-15.1 mmol/L/L; reference range, 2-7 mmol/L). Fifty-three dogs
(75%) had creatinine concentrations below the reference range and
no dogs (0%) had concentrations above the reference range (median,
72 umol/L; range, 35-132 umol/L; reference range, 100-133 umol/L).
3.2.4 | Treatment
Seven dogs (10%) received dietary treatment alone with either a com-
mercial therapeutic hydrolyzed or limited-ingredient novel protein or
GI low-fat diet. Six dogs (8%) received dietary treatment and antimi-
crobial treatment. Fifteen dogs (21%) received a combination of
dietary treatment and corticosteroid treatment and 17 dogs (24%)
received this combination with antimicrobial treatment. Nine dogs
(13%) received combined dietary treatment, corticosteroid and cyclo-
sporine and 12 dogs (17%) received this same combination with anti-
microbial treatment. Two dogs (3%) received a combination of dietary
treatment, corticosteroid, and azathioprine, and 3 dogs (4%) received
this same combination with antimicrobial treatment.
Sixty-four dogs (90%) received empirical deworming, 43 dogs
(61%) received parenteral cobalamin supplementation, and 12 dogs
(17%) received either low-dose aspirin or clopidogrel at standard
doses.
3.2.5 | Outcome
Twenty-six out of 71 dogs (37%) were alive at the end of the study
(n = 24 dogs) or were lost to follow-up (2), and 45 of 71 dogs (63%)
were dead. Of the 45 dogs that were dead at the end of the study,
15 died for reasons other than PLE, 3 died, and 27 were euthanized
after treatment failure. Of these 30 dead dogs, 9 failed to respond to
a combination of diet, antimicrobial, corticosteroid, and cyclosporine
treatment; 6 to a combination of diet, antimicrobial, and corticosteroid
treatment; 5 to diet and corticosteroid treatment; 6 to diet, cortico-
steroid, and cyclosporine treatment; 3 to diet, antimicrobial, cortico-
steroid, and azathioprine treatment; and 1 to diet, corticosteroid, and
azathioprine treatment. The median follow-up time (from the time of
PLE histologic diagnosis to death or end of the study, or to the last
observation recorded before the animal was lost to follow-up) was
240 days (minimum value - maximum value: 0-2250 days; interquar-
tile range: 1035 days). Median time to death or euthanasia after treat-
ment failure was 41 days (0-647; 121).
3.3 | Survival analysis
Results from all the univariable analyses including information on the
total number of dogs and events in each model can be found in
Table 1. After univariable screening, variables retained for multivari-
able modeling were CCEAI, urea (mmol/L), breed, serum albumin con-
centrations (g/L), and appetite. The most parsimonious model using
the AIC criterion was a multivariable model including CCEAI and urea
(mmol/L) as explanatory variables. The assumption of PH was met for
CCEAI (Z:ph test, P = .65), but it was not satisfied for urea (Z:ph test,
P = .006). Thus, urea was modeled as a covariate with a time-varying
effect, such that its regression coefficient varied as a linear function
of time t (f(t) = log(t + 1)) after adjusting for CCEAI. Results from the
final multivariable Cox PH regression model are shown in Table 2. At
any point in time after PLE histologic diagnosis caused by CE or lym-
phangiectasia, for each unit increase in CCEAI the dogs had experi-
enced, the hazard of death increased by 22.9% (95% confidence
interval [CI]: 6.9%-41.2%; Table 2), given that urea is held constant.
The time-dependent coefficient for urea is estimated to be ß(t) =
0.528-0.120 * log(t + 1) (P values <.01) (Table 2) indicating that urea
has a positive effect on death which decreases over time and drops
off by approximately day 80, given that CCEAI is held constant.
To further explore the association between CCEAI and survival in
dogs with PLE, we compared the Kaplan-Meier survival function of
2 groups of dogs formed based on a clinically relevant cutoff for
CCEAI of 8, as a CCEAI of ≤8 indicates a CE ranging from insignificant
to moderate, whereas a CCEAI of >8 denotes a CE ranging from
severe to very severe. The group of dogs with a CCEAI of ≤8 had sig-
nificantly longer survival time than the group with a CCEAI of >8
throughout the entire follow-up time period (P = .002; Figure 1).
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Median survival time of the dogs with a CCEAI of ≤8 and with a
CCEAI of >8 was undefined (95% CI: 647 - undefined; n = 32) and
109 days (95% CI: 6 - undefined; n = 21), respectively (Figure 1). After
following up the dogs for 647 days, the RMST of the dogs with a
CCEAI of ≤8 and with a CCEAI of >8 was 504.7 days (95% CI:
418.5-590.9; n = 32) and 248.6 days (95% CI: 126.6-370.5; n = 21)
respectively. Dogs with a CCEAI of ≤8 survived 256.1 days longer
(P = .001, 95% CI: 106.7–405.4) than those with a CCEAI of >8 on
average, when followed up for 649 days.
The association between urea and survival was further assessed
through comparing the Kaplan-Meier survival function of 2 groups of
dogs formed based on a cutoff of 7 mmol/L, as this was the upper end
of the laboratory reference range for urea. A value for urea of
≤7 mmol/L is considered normal based on our laboratory reference
range, whereas a urea value of >7 mmol/L indicates an increased
TABLE 1 Parameter estimates from a series of 16 univariable Cox proportional hazards regression models assessing the association between a
number of proposed markers of malnutrition and death after treatment failure in dogs with protein-losing enteropathy caused by chronic
enteropathy or lymphangiectasia
Variable Na nb β SEc Hazard ratio (95% CI)d P value
LRTe
Value DFf P value
Urea 53 23 0.341 0.093 1.407 (1.173-1.687) <.001 11.33 1 <.001
CCEAIg 53 23 0.220 0.068 1.246 (1.091-1.424) .001 10.16 1 .001
Appetite1 53 23 0.936 0.547 2.549 (0.873-7.444) .09 9.6 3 .02
Appetite3 53 23 −0.796 0.509 0.451 (0.166-1.223) .12
Appetite4 53 23 −1.435 1.045 0.238 (0.031-1.848) .17
Albumin (g/L) 53 23 −0.100 0.055 0.904 (0.812-1.007) .07 3.87 1 .049
Purebred (Yes) 53 23 1.115 1.023 3.051 (0.411-22.65) .28 1.7 1 .19
BCSh 53 23 −0.168 0.153 0.846 (0.626-1.142) .28 1.23 1 .27
Creatinine 53 23 0.010 0.009 1.011 (0.99-1.029) .26 1.22 1 .27
Age 53 23 0.060 0.073 1.062 (0.921-1.226) .41 0.7 1 .40
Signs duration 53 23 −0.001 0.001 0.999 (0.997-1.001) .48 0.56 1 .45
Sex (male) 53 23 0.180 0.427 1.198 (0.518-2.768) .67 0.18 1 .67
Neutered (Yes) 53 23 −0.146 0.506 0.864 (0.321-2.329) .77 0.08 1 .78
Percentage weight loss 53 23 −0.007 0.026 0.993 (0.943-1.046) .79 0.07 1 .79
Body weight 53 23 −0.001 0.017 0.999 (0.967-1.032) .95 0 1 .95
Cholesterol (mmol/L) 57 26 −0.351 0.187 0.704 (0.488-1.015) .06 4.04 1 .04
Cobalamin (pmol/L) 61 26 −0.003 0.002 0.997 (0.993-1.001) .12 3.28 1 .07
Folate (nmol/L) 61 24 −0.025 0.023 0.975 (0.932-1.02) .27 1.37 1 .24
aTotal number of dogs in the model.
bNumber of dogs dead or euthanized because of protein-losing enteropathy caused by chronic enteropathy or lymphangiectasia.
cStandard error.
d95% Confidence interval.
eLikelihood ratio test.
fDegrees of freedom.
gCanine chronic enteropathy activity index.
hBody condition score.
TABLE 2 Parameter estimates from a final multivariable Cox
proportional hazards regression model assessing the association
between proposed markers of malnutrition and death after treatment
failure in dogs with protein-losing enteropathy caused by chronic
enteropathy or lymphangiectasia
Variable β SEa
Hazard ratio
(95% CI)b
P
value
CCEAIc 0.206 0.071 1.229 (1.069-1.412) .004
Urea 0.528 0.126 1.695 (1.323-2.171) <.001
Time-transform
term (urea)
−0.120 0.046 0.887 (0.810-0.970) .01
a Standard error.
b 95% Confidence interval.
c Canine chronic enteropathy activity index.
FIGURE 1 Kaplan-Meier estimates of survival based on death after
treatment failure in 2 groups of dogs with protein-losing enteropathy
caused by chronic enteropathy or lymphangiectasia divided based on
the study population's median value for canine chronic enteropathy
activity index (CCEAI) of ≤8 (black line, n = 34) or >8 (red line, n = 26).
Marks in the lines indicate each censoring time
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concentration. The group of dogs with urea ≤7 mmol/L had signifi-
cantly longer survival time than the group with urea >7 mmol/L
throughout the entire follow-up time period (P = .0006; Figure 2).
Median survival time of the dogs with urea ≤7 and with urea >7 was
undefined (95% CI: 215 - undefined; n = 45) and 0.5 days (95% CI: 0 -
undefined; n = 8), respectively (Figure 2). After following up the dogs
for 647 days, the RMST of the dogs with urea ≤7 and with urea >7
was 443.4 days (95% CI: 362.9-523.8; n = 45) and 164.0 days (95%
CI: 29.38-357.3; n = 8) respectively. Dogs with urea ≤7 survived
279.4 days longer (P = .009, 95% CI: 70.0–488.7) than those with
urea >7 on average, when followed up for 649 days.
4 | DISCUSSION
The role of malnutrition in the prognosis of dogs with PLE caused by
CE or lymphangiectasia has not been extensively studied. Malnutrition
is an important comorbidity in human IBD patients with a prevalence
as high as 40%.19 Malnutrition is linked to adverse outcomes20,21 and
is associated with in-hospital death and increased hospital stay in
human IBD patients.8 Therefore, our study aimed to assess whether
markers associated with malnutrition in human IBD patients can be
used as predictors for death after treatment failure in dogs with PLE
caused by CE or lymphangiectasia. Our study showed that BCS, per-
centage weight loss, appetite and serum albumin, creatinine, cobala-
min, and folate concentrations were not significantly associated with
death in dogs with PLE caused by CE or lymphangiectasia after treat-
ment failure.
Our study did show a significant association between the CCEAI
and urea concentrations and death in dogs with PLE caused by CE or
lymphangiectasia. The CCEAI is an index for clinical severity, which is
associated with outcome in dogs with IBD and PLE.2,15 The CCEAI
was included as a marker of malnutrition in our study as severity of
disease is 1 of the variables used for nutrition risk screening in
humans as well as for the assessment of malnutrition in human
IBD.14,22 The CCEAI incorporates serum albumin concentrations, which
is a known laboratory marker for malnutrition. However, serum albumin
concentration changes caused by malnutrition are confounded by the
PLE because of loss into the intestinal tract and the effect of inflamma-
tion. This makes serum albumin concentrations difficult to use as a
definitive indicator of malnutrition in dogs with PLE. Similarly, loss of
cholesterol into the GI tract and malabsorption of cobalamin and folate
might also limit their usefulness in the assessment of malnutrition in dogs
with PLE. In our study, an increase in serum albumin concentration was
significantly associated with a reduction in the hazard of death in dogs
with PLE in the univariable Cox PH regression model. However, this vari-
able did not reach significance in the multivariable model. This may have
been because of decreased power of the study and therefore a larger
sample population might have resulted in a significant finding. If serum
albumin concentrations are significantly associated with death, this is
possibly an indicator of increased loss from the GI tract, and increased
inflammation, or a combination of this, together with malnutrition. The
concurrent measurement of fecal alpha 1 proteinase inhibitor and fecal
calprotectin in these cases might help to determine the contribution to
the hypoalbuminemia of enteric loss and inflammation, respectively, ver-
sus malnutrition. Such discrimination might then help to determine if
active dietary interventions in those cases with malnutrition help to
improve the response to treatment in dogs with PLE caused by CE or
lymphangiectasia. An increase in cholesterol concentration was signifi-
cantly associated with a reduction in the hazard of death in dogs with
PLE in the univariable Cox PH regression model. However, in order to
maximize the number of dogs included in the multivariable model, this
variable was excluded. Therefore, the effect of serum cholesterol con-
centration on death in dogs with PLE cannot be definitively confirmed.
The results of our study corroborate previous studies, in which
increased blood urea concentration is a negative prognostic indicator
in dogs with PLE.1,2 Possible causes of high urea include consumption
of a high protein diet, GI hemorrhage, increased protein catabolism
from starvation, prerenal causes because of severe diarrhea, kidney
disease, and postrenal causes. Renal and postrenal causes were unlikely
in our study; however, further prospective studies determining the
hydration status and muscle condition score as well as diet history and
presence of melena and hematochezia are needed to definitively ascer-
tain the cause of high urea in dogs with PLE caused by CE or lymphan-
giectasia. Interestingly, dogs that were euthanized or died before
discharge from the hospital (n = 4) had the highest urea concentrations
(Figure 2). Therefore, our study suggests that increased urea concentra-
tions might be predictive of in-hospital death in dogs with PLE caused
by CE or lymphangiectasia rather than death after discharge from the
hospital. However, because of the small number of in-hospital deaths in
our study, additional statistical analysis to determine which factors are
predictive of death in-hospital versus after discharge from the hospital
could not be performed. Additional studies are needed to determine a
cause or effect relationship of high urea (>7 mmol/L) and death as well
as determining if specific intervention in those dogs with high urea
(>7 mmol/L) might help to improve response to treatment and there-
fore prognosis.
In our study, body weight, percentage weight loss, and BCS were
some of the markers used to assess for malnutrition. However, given
FIGURE 2 Kaplan-Meier estimates of survival based on death after
treatment failure in 2 groups of dogs with protein-losing enteropathy
caused by chronic enteropathy or lymphangiectasia divided based on
the laboratory reference range cutoff for urea of ≤7 mmol/L (black
line, n = 45) or >7 mmol/L (red line, n = 8). Marks in the lines indicate
each censoring time
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the variability in size of different dog breeds, body weight is not as
informative of nutritional status as it is in humans. The reason for
inclusion of this variable was to determine if larger breed dogs had a
decreased response to immunomodulatory treatment compared to
smaller breed dogs. Percentage weight loss might have underesti-
mated the extent of malnutrition as nearly half of our cases had some
degree of abdominal effusion, peripheral edema, or both. The use of
BCS is informative of peripheral fat status in dogs; however, this score
does not take into account intra-abdominal fat, muscle condition, or
bone density, all of which can be reduced by malnutrition and are
therefore likely important in its assessment.23 Unfortunately, a major
limitation of our study was the absence of muscle condition score in
our cases and the effect of this on death after treatment failure.
Although, serum creatinine was used in our study as an attempt to act
as a surrogate for muscle condition, our study found that this was not
a prognostic marker. However, 75% of the dogs in our study had
serum creatinine concentrations below the reference range, which
indicates that muscle atrophy is likely prevalent in this disease.
Other limitations of our study include the retrospective study
design, which could have made the interpretation of the clinical his-
tory and assignment of the CCEAI score inconsistent because of mul-
tiple clinician involvement in the cases, especially because 3 of the
variables used for assessment of the activity index (lethargy, appetite,
and ascites and peripheral edema) involve a subjective scale.15 Also,
BCS is a subjective variable and therefore can differ between clini-
cians. Some variables, such as serum cholesterol concentrations or
appetite, were not assessed or reported in all cases. This limited the
number of dogs that were included in the statistical analysis, as only
dogs that had complete information for all covariates were included
(Table 1). Also, although all dogs in our study were normobilirubinemic
and did not have significant liver or biliary tree abnormalities on
abdominal imaging, pre- and postprandial bile acid concentrations to
eliminate hepatic dysfunction definitively were not measured for all
dogs. Similarly, renal function via the assessment of urinalysis
and early biochemical markers for glomerular filtration rate was not
assessed for all dogs. Therefore, the presence of possible concurrent
hepatic and renal dysfunction, although considered unlikely, could not
be definitively eliminated in all dogs. In our study, all but 1 of the
deaths related to PLE occurred within the first year of diagnosis and
also included 4 dogs that were euthanized or died before discharge
from the hospital; therefore, assessing the effects of malnutrition dur-
ing a specific time period might have allowed for tighter statistical
comparisons. Furthermore, regarding dogs that were censored because
they died of another cause, these were assumed to die of a competing
cause independent of the event in question. Consequently, interpreta-
tion of the survival analysis in our study in the presence of competing
risks is subject to at least some ambiguity because of uncertainty about
the degree of dependence among the competing outcomes. In our
study, the diagnosis of CE or lymphangiectasia for all cases was based
on histopathology of endoscopic biopsies and not all cases had ileal
biopsies performed; therefore, intestinal neoplasia might have been
missed in some cases, which would have then impacted the prognosis.1
Finally, the assessment of percentage weight loss in our cases was
dependent on previously recorded values by the referring veterinarian
and so any inaccuracies would have affected this measurement.
Similarly, differences in weighing scales as well as the dog's water bal-
ance, especially for those cases of dehydration, hypovolemia, ascites,
and peripheral edema could have impacted this measurement.
In conclusion, our study demonstrated that of the markers of mal-
nutrition studied, only the CCEAI and blood urea concentrations were
significantly associated with death in dogs with PLE caused by CE or
lymphangiectasia. Body condition score, body weight, percentage
weight loss, appetite, duration of signs and serum albumin, creatinine,
cobalamin, and folate concentrations at the time of histologic diagno-
sis could not be used as predictors of death after treatment failure in
dogs with PLE caused by CE or lymphangiectasia. Alternative mea-
sures of malnutrition such as muscle condition score and bone density
might be required to definitively investigate the role of malnutrition in
the prognosis of PLE in dogs.
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